抗高血压药物及其联合用药的降压疗效:随机双盲安慰剂对照试验的系统综述与荟萃分析
该系统综述与荟萃分析纳入484项随机双盲安慰剂对照试验、104 176名成人,评估五大类抗高血压药物及其联合用药的降压疗效。单药标准剂量平均降低收缩压8.7 mm Hg,双药联合标准剂量降低14.9 mm Hg;据此建立模型可将任意联合方案按降压强度分为低、中、高强度。
要点
- 单药标准剂量平均降低收缩压8.7 mm Hg,剂量每加倍额外降低1.5 mm Hg。
- 双药联合各一标准剂量降低收缩压14.9 mm Hg,两药剂量均加倍额外降低2.5 mm Hg。
- 基线收缩压每降低10 mm Hg,单药降压疗效减少1.3 mm Hg。
核心结论
- 分析提供了抗高血压药物任意联合方案预期降压效应的稳健估计,可将疗效分为低、中、高强度。
研究设计与样本
- 系统综述与荟萃分析,纳入比较血管紧张素转换酶抑制剂、血管紧张素II受体阻滞剂、β受体阻滞剂、钙通道阻滞剂或利尿剂的随机双盲安慰剂对照试验。
- 纳入标准为随访4至26周、随访血压评估前所有参与者固定抗高血压药物治疗至少4周、可获得诊所血压以计算治疗组间收缩压平均差。
- 排除交叉期洗脱不足2周的交叉试验;检索Cochrane对照试验中心注册库、MEDLINE和Epistemonikos,覆盖数据库建库至2022年12月31日,并更新至2023年1月1日至2025年2月28日。
- 共分析484项试验、104 176名参与者,平均年龄54岁(SD 8),57 422名(55%)男性、46 754名(45%)女性,平均基线血压154/100 mm Hg,平均随访8.6周(SD 5.2)。
- 主要结局为安慰剂校正的收缩压降低值,采用固定效应荟萃分析并标准化至纳入试验的平均基线血压;方案注册于INPLASY202410036。
主要发现
- 单药标准剂量平均降低收缩压8.7 mm Hg(95%CI 8.2-9.2),剂量每加倍额外降低1.5 mm Hg(95%CI 1.2-1.7)。
- 双药联合各一标准剂量降低收缩压14.9 mm Hg(95%CI 13.1-16.8),两药剂量均加倍额外降低2.5 mm Hg(95%CI 1.4-3.7)。
- 基线收缩压每降低10 mm Hg,单药降压疗效减少1.3 mm Hg(95%CI 1.0-1.5),但观察到药物类别间存在差异。
- 57种标准剂量单药中45种(79%)归为低强度;189种不同药物-剂量双药联合中110种(58%)归为中强度、21种(11%)归为高强度。
- 疗效模型在外部双药和三药联合试验中验证,预测与观察收缩压高度相关(r=0.76,p<0.0001)。
关键数值与推荐
- 药物方案按从基线154 mm Hg起的收缩压降压疗效分为低强度(<10 mm Hg)、中强度(10-19 mm Hg)和高强度(≥20 mm Hg)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We aimed to quantify the blood pressure-lowering efficacy of antihypertensive drugs and their combinations from the five major drug classes. METHODS: We conducted a systematic review and meta-analysis of randomised, double-blind, placebo-controlled trials involving adult participants randomly assigned to receive angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, β blockers, calcium channel blockers, or diuretics. Eligibility criteria included follow-up duration between 4 weeks and 26 weeks, antihypertensive drug treatment fixed in all participants for at least 4 weeks before follow-up blood pressure assessment; and availability of clinic blood pressure for the calculation of mean difference in systolic blood pressure between treatment groups. Crossover trials with less than 2 weeks' washout between the crossover periods were excluded. Eligible studies published between database inception and Dec 31, 2022 were identified from searches of the Cochrane Central Register of Controlled Trials, MEDLINE, and Epistemonikos; searches were updated to include studies published between Jan 1, 2023, and Feb 28, 2025. The primary outcome was placebo-corrected reduction in systolic blood pressure. Blood pressure-lowering efficacy was estimated using fixed-effects meta-analyses standardised to mean baseline blood pressure across included trials. Drug regimens were categorised into low, moderate, and high intensity, corresponding to systolic blood pressure-lowering efficacy of <10 mm Hg, 10-19 mm Hg, and ≥20 mm Hg, respectively, from a baseline of 154 mm Hg. A model was developed to calculate efficacy for any combination of antihypertensives and validated on external trials of dual and triple combination antihypertensives. The study protocol was registered on the International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY202410036). FINDINGS: We analysed 484 trials including 104 176 participants (mean age 54 years [SD 8], 57 422 [55%] men, 46 754 [45%] women, and mean baseline systolic blood pressure 154/100 mm Hg). Mean follow-up duration was 8·6 weeks (SD 5·2). On average, monotherapy at standard dose reduced systolic blood pressure by 8·7 mm Hg (95% CI 8·2-9·2), and each doubling in dose conferred an additional 1·5 mm Hg (1·2-1·7) reduction. Dual combinations at one standard dose conferred a 14·9 mm Hg (95% CI 13·1-16·8) reduction in systolic blood pressure, with each doubling of doses of both drugs conferring an additional reduction of 2·5 mm Hg (1·4-3·7). Each 10 mm Hg decrease in baseline systolic blood pressure reduced pressure-lowering efficacy by 1·3 mm Hg (1·0-1·5) for monotherapies, although differences between drug classes were observed. Among 57 monotherapies at standard dose, 45 (79%) were classified as low intensity. Of 189 different drug-dose dual combinations, 110 (58%) were classified as moderate intensity, and 21 (11%) as high intensity. There were considerable differences in dose-response and baseline blood pressure-response relationships between and within drug classes. The efficacy model showed a high correlation between predicted and observed systolic blood pressures when validated on external trials (r=0·76, p<0·0001). INTERPRETATION: These analyses provide robust estimates of the expected blood pressure-lowering effect for any combination of antihypertensive drugs, allowing their efficacy to be classified into low, moderate, and high intensity. FUNDING: National Health and Medical Research Council, Australia.
引用
- Wang N, Salam A, Pant R, et al. Blood pressure-lowering efficacy of antihypertensive drugs and their combinations: a systematic review and meta-analysis of randomised, double-blind, placebo-controlled trials. Lancet. 2025. PMID: 40885583. doi:10.1016/S0140-6736(25)00991-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。